整形外科重建產品市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、應用、最終用途、地區及競爭格局分類，2021-2031年）

全球整形外科重建產品市場預計將從 2025 年的 52.5 億美元成長到 2031 年的 69.6 億美元，複合年成長率為 4.81%。

此領域涵蓋生物工程解決方案，例如合成骨替代物、細胞療法和生長因子，旨在修復、替換和再生受損的肌肉骨骼組織，包括軟骨、骨骼和肌腱。推動該領域成長的主要因素是全球骨關節炎盛行率的不斷上升以及人口老化趨勢，這需要採用組織保護性治療方法來維持患者的活動能力。為了佐證這項需求，美國整形外科學會 (AAOS) 2024 年年會上公佈的數據預測，到 2040 年，老年人運動相關整形外科損傷將增加 123%，凸顯了對有效修復干預措施日益成長的需求。

儘管臨床需求旺盛，但由於報銷體係不統一和病患自付費用高昂，市場面臨許多障礙。許多公共和私人保險公司仍然將各種再生醫學藥物歸類為「研究性」或「實驗性」藥物，這阻礙了患者獲得這些藥物，並造成了經濟障礙，使得這些產品難以被廣泛納入標準醫療實踐。

市場促進因素

組織工程和生物材料領域的技術創新正在透過引入比傳統合成植入更有效的先進生物活性支架和細胞療法，改變整個產業。這些進步，尤其是在軟骨修復和皮膚替代物領域，正在克服捐贈者組織短缺的問題，並顯著縮短恢復時間，從而促進其在臨床環境中的快速應用。這些生物解決方案的商業性影響在自體細胞免疫療法領域領導者的財務表現中顯而易見。例如，Vericel公司在2024年11月發布的2024年第三季財務報告中顯示，其軟骨修復產品MACI的淨銷售額達到4,470萬美元，年成長19%，凸顯了組織工程產品在標準治療中日益廣泛的應用。

同時，運動相關傷害和各種其他傷害的發生率不斷上升，推動了再生醫學產品在活躍人群（從職業運動員到老年人）恢復功能方面的需求。隨著高強度運動參與度的提高，韌帶斷裂、肌腱損傷和軟組織損傷的發生率也隨之上升，促使人們研發能夠促進自然癒合的生物活性植入。這一趨勢支撐著擁有強大運動醫學產品組合的製造商（尤其是那些採用生物引導技術的製造商）的穩定收入成長。例如，史密斯醫療（Smith & Nephew）於2024年10月發布的2024年第三季交易報告顯示，其運動醫學和耳鼻喉科（ENT）部門的營收成長了3.9%，這體現了該市場的強勁勢頭。此外，史賽克（Stryker）宣布，其整形外科和脊椎部門僅在2024年第三季的淨銷售額就成長了10.7%，達到23億美元。

市場挑戰

全球整形外科再生醫學產品市場​​的擴張主要受制於限制性強且波動較大的醫保報銷環境。無論是公共醫療機構還是私人醫療機構，通常都將包括細胞注射劑和合成支架在內的再生醫學療法歸類為研究性療法而非醫療必需療法，導致醫保覆蓋範圍有限，迫使醫療機構要么應對繁瑣的核准流程，要么將成本轉嫁給患者。因此，儘管這些療法具有臨床吸引力，但由於未報銷治療帶來的巨大財務風險，醫院仍然不願意儲備這些昂貴的生物製藥。

這種財務摩擦直接限制了市場規模，因為它會造成行政障礙，延誤或阻止治療方案的實施。這些障礙的規模相當顯著；美國醫學會 (AMA) 報告稱，到 2024 年，27% 的醫生將頻繁遭遇預先核准申請被拒的情況。這項挑戰對需要詳細理由說明的新型治療方法影響尤為嚴重。當支付方持續拒絕理賠或強制要求高額自付費用時，患者的接受度就會降低，從而限制製造商的獲利潛力，並減緩整個行業的商業性發展。

市場趨勢

微創再生醫學手術的趨勢正在從根本上重塑肌肉骨骼護理，將複雜的治療從住院機構轉移到門診手術中心（ASC）。這項轉變得益於高解析度關節鏡和可注射骨生物製藥的結合，使外科醫生能夠植入生物活性基質，從而減少組織損傷並加快恢復速度。這種營運模式轉變的商業性成功體現在專注於先進整形外科服務的門診機構的擴張上。值得注意的是，在2024年11月的第三季財報電話會議上， 果凍 Partners宣布其門診手術中心的全關節置換術數量年增超過50%，顯示手術量正迅速向高效的門診再生醫學模式轉變。

同時，羊膜和胎盤組織同種異體移植的應用日益廣泛，成為自體組織採集的可行替代方案。它們富含抗發炎細胞激素，是一種即用型解決方案。與需要額外手術部位進行組織採集的自體組織採集方法不同，這些同種異體移植能夠即時釋放生物訊號，抑制疤痕形成，促進癒合，適用於從肌腱修復到脊椎融合手術等多種手術。市場對胎盤衍生生質材料公司的財務表現也印證了這一點。例如，MiMedx集團在2024年10月發布的「2024年第三季營運與財務業績」報告中指出，其胎盤組織產品的淨銷售額達到8,400萬美元，這主要得益於其專業外科產品線的貢獻成長。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球整形外科與重建外科產品市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（同種異體移植、黏彈性替代物、合成材料、細胞基材料）
  • 按應用領域（整形外科疼痛管理、創傷修復、軟骨和肌腱修復、關節重組等）
  • 依最終用途（醫院、門診手術中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美整形外科和重建產品市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲整形外科和重建產品市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區整形外科及重建產品市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東及非洲整形外科及重建外科產品市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲整形外科與重建產品市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球整形外科重建產品市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zimmer Biomet Holdings Inc.
• Baxter International Inc.
• Stryker Corporation
• Smith+Nephew Plc
• AMillioniox Medical, Inc.
• Vericel Corporation
• Anika Therapeutics, Inc.
• Aptissen SA
• Vsy Biotechnology GmbH
• Enovis Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Orthopedic Regenerative Surgical Products Market is projected to expand from USD 5.25 Billion in 2025 to USD 6.96 Billion by 2031, exhibiting a compound annual growth rate of 4.81%. This sector includes biologically engineered solutions such as synthetic bone substitutes, cellular therapies, and growth factors aimed at repairing, replacing, or regenerating damaged musculoskeletal tissues like cartilage, bone, and tendons. Growth is primarily underpinned by the increasing global prevalence of osteoarthritis and the demographic shift toward an aging population necessitating tissue-preserving treatments to sustain mobility. Reinforcing this demand, data presented at the 2024 annual meeting of the American Academy of Orthopaedic Surgeons forecasted a 123% rise in sports-related orthopedic injuries among the elderly by 2040, highlighting the growing need for effective restorative interventions.

Despite strong clinical demand, the market encounters significant obstacles due to inconsistent reimbursement structures and substantial out-of-pocket expenses. Numerous public and private insurers persist in labeling various regenerative therapies as investigational or experimental, establishing financial barriers that hinder patient access and constrain the broad integration of these products into standard medical practice.

Market Driver

Technological innovations in tissue engineering and biomaterials are transforming the industry by introducing advanced biologically active scaffolds and cellular therapies that integrate more effectively than traditional synthetic implants. These developments, especially within cartilage repair and skin substitutes, are fostering rapid clinical adoption by overcoming donor tissue shortages and significantly shortening recovery periods. The commercial impact of these biologic solutions is demonstrated by the financial results of major companies in autologous cellular immunotherapies; for instance, Vericel Corporation reported in its Third Quarter 2024 Financial Results in November 2024 that net revenue for its MACI cartilage repair product rose by 19% year-over-year to $44.7 million, highlighting the increasing use of tissue-engineered options in standard care.

Concurrently, the escalating incidence of sports-related injuries and trauma is fueling the demand for regenerative products designed to restore function across active populations, from professional athletes to seniors. As engagement in high-impact activities grows, the prevalence of ligament tears, tendon injuries, and soft tissue trauma has driven the creation of bioactive implants that accelerate natural healing. This trend supports steady revenue growth for manufacturers with strong sports medicine portfolios, particularly those incorporating bio-inductive technologies. Illustrating this market strength, Smith+Nephew's Third Quarter 2024 Trading Report in October 2024 noted a 3.9% revenue increase in its Sports Medicine & ENT segment, while Stryker reported in 2024 that net sales in its Orthopaedics and Spine segment grew by 10.7% to reach $2.3 billion in the third quarter alone.

Market Challenge

The expansion of the global orthopedic regenerative surgical products market is primarily hindered by a restrictive and variable reimbursement environment. Both public and private payers often categorize regenerative treatments, including cell-based injections and synthetic scaffolds, as investigational rather than medically essential, resulting in limited coverage policies that require providers to manage difficult approval procedures or pass costs to patients. As a result, despite clinical appeal, hospitals remain reluctant to stock these expensive biologics due to the substantial financial risk associated with uncompensated care.

This financial friction directly limits market volume by generating administrative hurdles that delay or block treatment administration. The scale of this barrier is significant; the American Medical Association reported in 2024 that 27% of physicians frequently experienced denials for prior authorization requests, a challenge that particularly impacts novel therapies needing detailed justification. When payers consistently reject claims or mandate high out-of-pocket payments, patient uptake slows, effectively limiting the revenue potential for manufacturers and retarding the sector's overall commercial progress.

Market Trends

The trend toward minimally invasive regenerative procedures is fundamentally reshaping musculoskeletal care by moving complex treatments from inpatient hospitals to ambulatory surgery centers (ASCs). This shift is facilitated by combining high-resolution arthroscopy with injectable orthobiologics, enabling surgeons to implant bioactive matrices with reduced tissue disruption and faster recovery times. The commercial success of this operational change is clear in the expansion of outpatient facilities focusing on high-acuity orthopedic services; notably, Surgery Partners stated in their Third Quarter 2024 Earnings Call in November 2024 that total joint replacement cases in their ASCs grew by over 50% year-over-year, demonstrating a rapid movement of surgical volume toward efficient, outpatient regenerative models.

At the same time, the increasing use of amniotic and placental tissue allografts is emerging as a strong alternative to autologous harvesting, providing off-the-shelf solutions abundant in anti-inflammatory cytokines. Unlike autologous methods that require additional surgical sites for tissue collection, these allografts deliver immediate biological signaling to reduce scarring and improve healing in procedures ranging from tendon repair to spinal fusion. Market acceptance is evident in the financial performance of companies specializing in placental-based biomaterials; for example, MiMedx Group, Inc. reported in its Third Quarter 2024 Operating and Financial Results in October 2024 that net sales for its placental tissue products hit $84 million, supported by the rising contribution of its specialized surgical lines.

Key Market Players

• Zimmer Biomet Holdings Inc.
• Baxter International Inc.
• Stryker Corporation
• Smith+Nephew Plc
• AMillioniox Medical, Inc.
• Vericel Corporation
• Anika Therapeutics, Inc.
• Aptissen S.A
• Vsy Biotechnology GmbH
• Enovis Corporation

Report Scope

In this report, the Global Orthopedic Regenerative Surgical Products Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orthopedic Regenerative Surgical Products Market, By Product

• Allografts
• Viscosupplements
• Synthetic
• Cell-based

Orthopedic Regenerative Surgical Products Market, By Application

• Orthopedic Pain Management
• Trauma Repair
• Cartilage & Tendon Repair
• Joint Reconstruction
• Others

Orthopedic Regenerative Surgical Products Market, By End-use

• Hospitals
• Ambulatory Surgical Centers
• Others

Orthopedic Regenerative Surgical Products Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orthopedic Regenerative Surgical Products Market.

Available Customizations:

Global Orthopedic Regenerative Surgical Products Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orthopedic Regenerative Surgical Products Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Allografts, Viscosupplements, Synthetic, Cell-based)
  • 5.2.2. By Application (Orthopedic Pain Management, Trauma Repair, Cartilage & Tendon Repair, Joint Reconstruction, Others)
  • 5.2.3. By End-use (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Orthopedic Regenerative Surgical Products Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Orthopedic Regenerative Surgical Products Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Orthopedic Regenerative Surgical Products Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Orthopedic Regenerative Surgical Products Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-use

7. Europe Orthopedic Regenerative Surgical Products Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-use

8. Asia Pacific Orthopedic Regenerative Surgical Products Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Orthopedic Regenerative Surgical Products Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Orthopedic Regenerative Surgical Products Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Orthopedic Regenerative Surgical Products Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Orthopedic Regenerative Surgical Products Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-use

10. South America Orthopedic Regenerative Surgical Products Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Orthopedic Regenerative Surgical Products Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Orthopedic Regenerative Surgical Products Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Orthopedic Regenerative Surgical Products Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Orthopedic Regenerative Surgical Products Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zimmer Biomet Holdings Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. Stryker Corporation
• 15.4. Smith+Nephew Plc
• 15.5. AMillioniox Medical, Inc.
• 15.6. Vericel Corporation
• 15.7. Anika Therapeutics, Inc.
• 15.8. Aptissen S.A
• 15.9. Vsy Biotechnology GmbH
• 15.10. Enovis Corporation

16. Strategic Recommendations

17. About Us & Disclaimer